Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21220040 | 1.00 | PDE4A (0.35) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL19784110 | 1.00 | PDE4A (0.35) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL21220083 | 0.92 | P2RX7 (0.35) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL19784175 | 0.92 | P2RX7 (0.35) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL18313686 | 0.90 | P2RX7 (0.34) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL20531975 | 0.90 | P2RX7 (0.34) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL20532165 | 0.90 | P2RX7 (0.34) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL22331764 | 0.90 | P2RX7 (0.34) | PDE4AKCNH2PDE4BPDE4CPDE4D | |
| SCHEMBL19783950 | 0.89 | ULK1 (0.34) | KCNH2 | |
| SCHEMBL19783951 | 0.89 | ULK1 (0.34) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481823-B1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| WO-2018011017-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | GLS, TNNI3, AADAC | PDE4A 793/4885KCNH2 1611/4885PDE4B 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.